Barrington raised the firm’s price target on U.S. Physical Therapy (USPH) to $103 from $98 and keeps an Outperform rating on the shares. Q2 revenue “exceeded our Street-high estimate” and adjusted EPS also came in “well above” the firm’s expectation and consensus, notes the analyst, who raising the firm’s 2025 and 2026 adjusted EBITDA estimates following the report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on USPH:
- U.S. Physical Therapy Reports Strong Q2 2025 Results
- US Physical Therapy Reports Record Q2 2025 Results
- Balanced Outlook: U.S. Physical Therapy’s Strong Earnings and Pricing Challenges Justify Hold Rating
- U.S. Physical Therapy reports Q2 operating EPS 81c, consensus 69c
- U.S. Physical Therapy sees FY25 adjusted EBITDA $93M-$97M